I n this issue of the Journal, Romero et al 1 report the results of an individual patient data (IPD) meta-analysis on the use of daily vaginal progesterone in women with a midtrimester short cervix (25 mm) in the prevention of preterm birth (PTB).
I n this issue of the Journal, Romero et al 1 report the results of an individual patient data (IPD) meta-analysis on the use of daily vaginal progesterone in women with a midtrimester short cervix (25 mm) in the prevention of preterm birth (PTB).
An IPD meta-analysis is a type of systematic review in which the original research data for each participant of each study are sought directly from the investigators responsible for the studies. The IPD approach enables data verification, reanalysis of the data in a consistent way, and standardization of outcomes across trials and allows the investigation of whether an intervention is more or less effective for different patient subgroups.
Romero et al 1 analyzed data from 5 high-quality randomized controlled trials and demonstrated that allocation to vaginal progesterone was associated with a significant decrease in the risk of PTB occurring at <28 to <36 weeks of gestation. There was also a significant reduction in the frequency of respiratory distress syndrome, composite neonatal morbidity and mortality, birthweight <1500 g and <2500 g, and admission to the neonatal intensive care unit. Moreover, there was a clear trend toward a decrease in the risk of neonatal death and the requirement for mechanical ventilation.
The subtext of this important work is a call for a change in how we practice obstetrics. This editorial will explore the rationale for, and feasibility of, such a change. To begin with, I will briefly describe the background of this paper.
Preterm birth, with its collateral effects on neonatal mortality, short-and long-term infant morbidity and astronomical healthcare costs, is the foremost problem in modern obstetrics. In developed countries 75% of perinatal mortality occurs in preterm babies, but greater attention is now being focused on early preterm births (<32 weeks of gestation), which represent 1e2% of all births but account for about 60% of all neonatal mortality and nearly 50% of all long-term neurological morbidity. 2, 3 The morbidities include respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis, sepsis, and retinopathy of prematurity. Long-term complications include cognitive disorders, social and behavioral problems, and cerebral palsy.
This recital of the well-known complications of preterm birth does not convey the devastating financial, social, and emotional effects on the parents or the affected children. 4 In the United States, the short-term hospital costs during the first year of life of preterm birth/low-birthweight infants, were estimated to be $5.8 billion, 5 and estimates for the annual societal economic burden in the United States was at a minimum, $26.2 billion in 2007. 6 These costs have certainly increased in the last decade. These facts will be well known to some readers of this Journal, but they bear repeating because whatever issues are discussed in this editorial, they exist in the background-the enormous human and financial cost of PTB.
The overall PTB rate peaked in the United States in 2006 at 12.8% and fell by 14% until 2014, a decrease attributed by some to the remarkably successful campaign to reduce the number of teenage pregnancies 7 ; however, it has risen again over the past 2 years and now stands at 9.8%, 8 which is higher than most European countries where rates vary from 5% to 9%, with the lowest rates in the Nordic countries. 7 Most estimates of gestational age in the United States are based on the last menstrual period, which have a systematic tendency to overestimate the duration of pregnancy. 9 This has led to the belief that if first-trimester ultrasound estimates were adopted in America as in Europe, the PTB rates would fall, 7 which might be true for late iatrogenic preterm births but may increase the recorded number of early spontaneous PTBs.
Spontaneous preterm birth with or without prelabor rupture of the membranes accounts for two thirds of PTBs, 10 with the remainder occurring as a result of obstetrically indicated preterm delivery. Spontaneous PTBs are the biggest challenge because they are highly represented in early PTB and are associated with a higher mortality and a greater number of neonatal complications.
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For many years women with a history of spontaneously delivering a baby preterm were the focus of preventative treatment such as cerclage 12 or synthetic progestogen in the form of 17-alpha hydroxyprogesterone caproate (17OHP-C) injections 13, 14 with some reported success. However, although a history of spontaneous PTB confers a higher risk for recurrent PTB, it accounts for only 7% of women who deliver prematurely, 15 so although important for the individual couples, this has made little impact on the overall problem of spontaneous PTB rates.
In the 1980s, attempts were made to stop premature labor with a variety of tocolytic agents, but this was not successful 16 in significantly prolonging gestation and this treatment is used now only to delay birth for 48 hours to allow steroid therapy or allowing maternal transfer to an appropriate center equipped for optimal neonatal care.
The reasons for this failure came with a greater understanding of the role of progesterone in the etiology of spontaneous PTB. This is discussed at length by Romero et al 1 in the IPD meta-analysis published today. Progesterone promotes myometrial quiescence and inhibits cervical ripening by downregulating the production of cytokines and also has effects on the chorioamniotic membranes. 17, 18 Premature initiation of cervical shortening is proposed to be due to a functional progesterone blockade, which may lead to a loss of the mucus plug (which has antimicrobial properties) 19, 20 and a variable grade intraamniotic inflammation. [21] [22] [23] [24] [25] Unscheduled sonographic shortening of the cervix, which is a manifestation of cervical effacement, is part of the terminal common pathway in a substantial number of cases of spontaneous preterm births.
Concurrent with these new concepts came the discovery that a sonographic short cervix in the midtrimester 26, 27 was associated with an increased risk of spontaneous PTB in women with single and multiple gestations, irrespective of whether they had a history of PTB. Various cutoffs were assessed, but the consensus is now settling on a cervical length of 25 mm at 18e24 weeks' gestation as identifying about 50% of spontaneous PTBs and providing the best likelihood ratios for birth before 32 and 34 weeks.
Goldenberg et al 28 in a US population found that 1.9% of unselected women who delivered <32 weeks' gestation had a cervical length <25 mm at 22e24 weeks; 48% of these were detected with a positive likelihood ratio of 5.35, fulfilling the criteria for a moderately useful screening test. 29 Barros-Silva et al 30 in a detailed meta-analysis of 16 studies concluded that a positive relationship was established between short cervix and preterm delivery in virtually all studies.
The majority of these studies showed a high specificity and positive likelihood ratio, while the sensitivity and negative likelihood ratio were variable and globally poor. This is to be expected because spontaneous PTB is a heterogeneous condition with many aetiological pathways. 31 A short cervix serves to identify one of many pathways, albeit a very important one.
The Fetal Medicine Foundation in London, United Kingdom, developed a model to predict preterm birth based on observations in more than 39,000 consecutive unselected pregnant women by combining maternal risk factors such as age and history of PTB with midtrimester cervical length. 32 The authors reported that the prediction of preterm delivery before 32 weeks at a fixed false-positive rate of 10% was 38% for maternal factors (including previous spontaneous PTB, maternal age, ethnic group, body mass index, cigarette smoking, and previous cervical surgery), 55% for cervical length, and 69% for combined testing. 32 The next step of this story was the introduction of vaginal progesterone either as a gel containing 90 mg natural progesterone or as a 200 mg vaginal tablet containing micronized natural progesterone. This treatment has been used for 25 years in in vitro fertilization programs for luteal support following embryo transfer 33 and is licensed on both sides of the Atlantic for this indication.
Vaginal progesterone generates higher levels of endometrial progesterone compared with intramuscular progesterone despite lower blood concentrations of progesterone, suggesting a mechanism of direct transport between the vagina and endometrium. 34, 35 As a result, vaginal progesterone, which has an excellent safety profile and few side effects in the doses described in the previous text, appears to be particularly suited to arresting or preventing cervical shortening and decreasing the risk of spontaneous PTB in this subgroup of patients. 36 Two multicenter randomized clinical trials showed that vaginal progesterone in women with a short cervix in midgestation reduced the rate of preterm birth (defined as births at <34 or <33 weeks of gestation) by 44e45%. 37, 38 A subsequent IPD meta-analysis 39 of 5 high-quality trials including 775 women (388 allocated to vaginal progesterone, 387 allocated to placebo) showed that vaginal progesterone, in addition to significantly reducing spontaneous PTB at <28 to <35 gestational weeks, significantly reduced admissions to the neonatal intensive care unit, the rate of respiratory distress syndrome, the requirement for mechanical ventilation, and composite neonatal morbidity/mortality. This resulted in a call for the implementation of universal cervical length screening for all pregnant women between 18 and 24 weeks of gestation and vaginal progesterone for those with a cervical length of 25 mm. 40 Subsequently the Society for Maternal-Fetal Medicine, 41 the American College of Obstetricians and Gynecologists, 42 and the National Institute for Health and Care Excellence 43 recommended vaginal progesterone treatment in women with a sonographic short cervix in the midtrimester but stopped short of recommending universal screening for cervical length. However, the International Federation of Gynecology and Obstetrics 44 has endorsed universal cervical length screening.
The consensus that vaginal progesterone was effective in the prevention of spontaneous PTB in women with a singleton gestation and a short cervix was disturbed after the publication of a large Medical Research Councilefunded multicenter trial (OPPTIMUM) from the United Kingdom 45 involving 1228 women with singleton pregnancies, which found no effect of vaginal progesterone on reducing PTB at Editorials ajog.org <34 weeks or fetal death, a composite of neonatal morbidity and mortality, or cognitive scores in children at 2 years of age.
The inclusion criteria at the commencement of the study in 2008 were based on a history of PTB or cervical surgery and a positive fetal fibronectin test and did not include cervical length measurements, but these were included after an early interim analysis. Measurements were not performed on a universal screening basis but on individual physician's request (undefined).
Romero et al 1 have in today's issue presented an updated version of their IPD meta-analysis, 39 including individual patient data from the OPPTIMUM trial (generously provided by Professor Jane Norman of the United Kingdom) from women who had cervical length measurements performed in this trial. The inclusion of these data in the new IPD meta-analysis now includes 974 women (498 receiving vaginal progesterone, 476 placebo) and has resulted in a stronger beneficial effect of vaginal progesterone in women with a short cervix of 25 mm. The new finding is that vaginal progesterone administered to women with a midtrimester short cervix significantly reduces the risk of preterm birth over a wide range of gestational ages (beginning at <28 weeks and extending to <36 weeks) and birthweight <2500 g.
The significant reduction in respiratory distress syndrome previously described 39 was confirmed but not strengthened because information about the occurrence of respiratory distress was not collected in the OPPTIMUM study. The authors have in this issue renewed the previous recommendation from this group for universal cervical length measurement at 18e24 weeks and vaginal progesterone treatment for those with a short cervix.
The benefits of vaginal progesterone in women with a short cervix are not achieved with the administration of 17OHP-C. For example, vaginal progesterone has been shown to be effective in women with a short cervix, while 17OHP-C was not. 46 There is now evidence that natural and synthetic progestogens are not equivalent and that their efficacy, indications, and safety profile are different. 14 In conclusion, there is now convincing evidence that vaginal progesterone given to women with a short cervix in midgestation reduces the risk of PTB by approximately 40% across all gestational ages before 37 weeks with a significant reduction in neonatal mortality and morbidity. Is there an alternative to vaginal progesterone? Two alternatives to vaginal progesterone for women with a short cervix are currently being considered in clinical practice. Cervical cerclage has been used for 50 years in the treatment of women with congenital or acquired weakness of the cervix. 47 This is usually diagnosed following an early second-trimester miscarriage and the appearance of cervical shortening in a subsequent gestation, so it is a reasonable assumption that the short cervix associated with spontaneous PTB may also be amenable to cerclage.
Initial studies indicated that there was a beneficial effect in women with a prior spontaneous PTB and a short cervix in midgestation, 48 but the authors of a meta-analysis postulated that some of the women who benefited may have had an element of true cervical insufficiency.
A recent meta-analysis 49 of 5 randomized controlled trials comparing cerclage with no cerclage including 419 singleton gestations without prior spontaneous preterm birth and a cervical length <25 mm found no statistical differences in spontaneous PTB <35 weeks to <24 weeks or improved neonatal outcome in the cerclage group. In subgroup analyses there was a weak effect of cerclage in women with a cervical length <10 mm, women who received tocolytics, and those who received antibiotics.
Vaginal progesterone may be less effective in women with cervical lengths <10 mm, which were excluded from the study of Hassan et al, 38 so the role of cerclage and antibiotics 50 should continue to be investigated in this subgroup of women. The Arabin pessary 51 is an alternative less invasive approach to cerclage, but there is lack of agreement as to its efficacy in women with a short cervix in the midtrimester. [52] [53] [54] [55] [56] Weekly injections of 17OHP-C have been used extensively in women with a history of spontaneous PTB for more than 25 years. This treatment gained popularity in the United States following a double-blinded study 13 of 310 women given 17OHP-C and 153 placebo, which found a significant reduction in spontaneous PTB before 37, 35, and 32 weeks.
Subsequently a secondary analysis of patients given 17OHP-C as part of a large trial of cerclage in women with previous spontaneous PTB 57 and a short cervix showed no additional benefit of 17OHP-C over cerclage but some effect when given alone. However, 2 recent studies have not supported its use.
A recent prospective cohort study 58 recruited 430 consecutive women with prior births 35 weeks who were treated with 17OHP-C and compared the pregnancy outcome against those of a historical control group; the overall rate of recurrent preterm birth was 25% for the cohort compared with 16.8% as the historical referent rate. Additionally, a randomized controlled trial 59 of 17OHP-C in women at high risk for preterm delivery with a short cervix was ended early after an interim analysis showed no evidence of an effect and a continuation of the trial was considered futile.
The lack of effect of 17OHP-C in this population has been attributed to the fact that 17OHP-C, unlike vaginal progesterone, does not prevent shortening of the cervix. 60 In conclusion, vaginal progesterone appears to be the prophylactic method of choice for women with a short cervix in the midtrimester.
Is vaginal progesterone effective in twin gestations?
Preterm birth is the most important factor determining neonatal morbidity and mortality among twin gestations. More than 50% of women with a dichorionic or monochorionic twin pregnancy will give birth prematurely, and the ajog.org Editorials risk of preterm birth <37 and <32 weeks' gestation is 8-to 9-fold higher in twins than in singleton gestations.
The IPD meta-analysis in this issue concerns preterm birth in singleton gestations but because cervical length in midtrimester 61 is even more predictive of spontaneous PTB in twins than singletons, it would be reasonable to explore whether vaginal progesterone would be effective in the prevention of spontaneous PTB in twins. In other words, should twin gestations be included in a universal cervical length screening program?
The effect of vaginal progesterone in asymptomatic twin pregnancies with a midtrimester short cervix (25 mm) was analyzed in an IPD meta-analysis 62 of 6 randomized controlled trials (159 assigned to vaginal progesterone and 144 assigned to placebo/no treatment). Administration of vaginal progesterone to women with a twin gestation and a sonographic short cervix in the midtrimester reduced the risk of preterm birth occurring at <30 to <35 gestational weeks, neonatal mortality, and some measures of neonatal morbidity, without any demonstrable deleterious effects on childhood neurodevelopment.
More data are required to assess the effect of vaginal progesterone in twin gestations with a short cervix because it appears that the same mechanism of the shortening of the cervix might be operating in twins as in singletons and that vaginal progesterone might be beneficial in the subgroup of twins with a short cervix. In view of the high incidence of short cervix in a twin gestation, this could be an important development.
An important etiological factor in twin gestations is assisted conception, especially in vitro fertilization (IVF) treatment. IVF is responsible for 1.6% of all births but 36% of all twins and 76% of triplets born in the United States. 63 The rate of twin gestation has fallen slightly in the last few years because of the move toward single blastocyst transfer, but the incidence remains unacceptably high. Research in IVF twins is needed to establish whether vaginal progesterone is effective in this subgroup.
Performance of universal cervical length assessment in singleton gestations
This will depend on the population being studied, the cervical length cutoff used (ie, 15 mm, 20 mm, 25 mm) the gestational age of the screen, the prevalence of both spontaneous PTB and short cervix in the population being screened, and the gestational age threshold to be predicted (eg, <34 weeks, <32 weeks).
There is a consensus growing that by increasing the cutoff to 25 mm, the sensitivity will improve, although this will be at the expense of lowering the positive predictive value. A high sensitivity is desirable to include as many high-risk women to have treatment. There is also a growing consensus that the screening should be done between 18 and 24 weeks' gestation, presumably to fit in with the gestation of the second-trimester fetal anatomic survey.
It is unlikely that the performance will be the same at each end of this time period, and further research is needed to identify the optimum timing window. For example, Heath et al 64 in a large observational study achieved excellent results by screening at 23 weeks, with 58% of women who delivered <32 weeks being identified with a cervical length 15 mm.
With a first-trimester scan now being used to identify the majority of anatomic and chromosome anomalies, the midtrimester scan would perhaps be more useful at 22e24 weeks when the cervical length performance might be more effective as would uterine artery Doppler to predict preeclampsia and fetal growth restriction. After all, the uterine artery is only 2 cm lateral to the cervix.
Performance will also be determined by compliance for screening. Temming et al 65 in a large study of women offered a cervical length measurement at the fetal anatomic survey found that women with singleton gestations were more likely to decline cervical length screening if they were African American, obese, multiparous, younger than 35 years, or smoked; rates of spontaneous preterm birth before 28 weeks were higher in those who declined the measurement. Screening directed only to women deemed to be high risk on maternal characteristics would, I believe, be regarded as discriminatory.
Compliance is vitally important. A sense of we are all in this together should be engendered among patients and a public health program would help to achieve this aim. Some of the real-world studies discussed in the following text have successfully done this.
Esplin et al 66 in a multicenter observational study of 9410 women found that cervical length screening had a low area under the receiver-operating characteristic curve (0.67) for predicting spontaneous PTB. In this observational study, there were 2 previously unresearched screening gestations: 16e22 and 22e30 weeks. Screening in the later period at a cutoff 25 mm identified only 23.3% of cases of spontaneous preterm birth <37 weeks but 52% of women who delivered before 32 weeks, which would have allowed treatment in this vulnerable group.
The authors calculated that a routine measurement at 16e22 weeks would entail 247 women being screened to identify 1 case of spontaneous PTB before 37 weeks. This mirrors calculations of Parry et al 67 using data from the randomized trial of Fonseca et al 37 based on a hypothetical cohort of 10,000 women; they calculated that 25 preterm births <34 weeks would be prevented by universal cervical length assessment and vaginal progesterone treatment and that 400 ultrasound examinations for each of these spontaneous PTBs would be required to achieve this effect.
The equivalent calculation for the study by Hassan et al 38 for spontaneous PTB <33 weeks was 17 and 588. These figures would come as no surprise to physicians involved in screening programs. For example, for cervical cancer 1140 women will have a smear for every invasive cancer detected. 68 Screening requires hard work, but the dividend for future generations of citizens should never be forgotten.
Costs required of introducing a nationwide program
Bloom and Leveno 69 in a provocative commentary entitled Unproven technologies in maternal-fetal medicine threw Editorials ajog.org down the gauntlet on costs of introducing a cervical screening program in the United States calculating that universal cervical length screening would incur approximately $175 million in actual health care expenditures per year. The cost of a transvaginal ultrasound scan for cervical length in their rather back-of-the-envelope analysis of expenditure was $237. The authors did not discuss any of the 6 detailed costeffectiveness analyses, [70] [71] [72] [73] [74] [75] all of which showed that universal screening was cost saving or cost effective, depending on the incidence of short cervical length at screening.
Werner et al 71 in their original cost analysis model predicated his calculation on an incidence of spontaneous PTB <34 weeks of 2.1% and a prevalence of 1.7% for cervical length <15 mm at 18e24 weeks. Using standard costing estimates of neonatal and long-term care, the authors found that universal cervical length screening and vaginal progesterone were cost saving compared with no screening.
More recently this group of investigators 72 revised their calculations and found that even with an incidence as low as 0.8% for cervical length 20 mm at screening and an incidence of 1.3% for spontaneous PTB <34 weeks, the model showed that universal screening was cost effective compared with no screening.
Einerson et al 73 in their economic model demonstrated that a policy of universal cervical length screening and vaginal progesterone excluding women with previous spontaneous PTB was more cost effective than screening a high-risk population only (including African-American or Hispanic race/ethnicity, tobacco use, previously indicated PTB or cervical surgery) or no screening. Therefore, universal cervical length screening is either cost saving or cost effective, depending on the prevalence of both spontaneous PTB and short cervix in the population being screened.
Implementing a screening program
In most developed countries including the United States, 76 a midtrimester ultrasound examination is standard of practice, principally to study fetal anatomy, determine placental location, identify multiple gestations, and early fetal growth restriction. If universal cervical length measurement was introduced, it is reasonable to expect that it would be conducted by the same sonographer who performs the fetal anatomy scan, which is a highly skilled examination.
The cervical length examination to measure the functional cervix is relatively easy for an experienced sonographer. Most midtrimester scans are performed by the sonographer facing the woman so the initiation of a transvaginal scan could take place without the woman changing position or the bed being moved. Obviously it is very important that the examination is performed properly according to the recommendations of organizations such as the Fetal Medicine Foundation or the Society for Maternal-Fetal Medicine sponsored certification method, 41 and images of the measurement should be stored for audit.
In a well-organized department, the examination should take no more than 10 minutes. However, it is usually recommended to observe the cervix for about 30 seconds after the external and internal os have been visualized to detect dynamic changes that will shorten the functional length of the cervix; this process can be speeded up by 10 seconds of gentle fundal pressure.
The debate about transabdominal scanning of the cervix, I believe, is already lost in favor of transvaginal ultrasound screening. Women are now accustomed to transvaginal ultrasound scans in gynecology and fertility clinics, and in the United Kingdom, it is rare to receive a request from a patient for a transabdominal scan, especially if it is explained that transvaginal ultrasound is more accurate, 77, 78 is not subject to artefact and shadowing, and any measurement <35 mm would have to be checked by a transvaginal scan anyway. 79 In the study of Son et al 80 described in the following text, 17,590 women accepted transvaginal ultrasound for cervical length (ie, 99.9% of eligible women).
Does universal transvaginal sonographic cervical length assessment and vaginal progesterone work in the real world? Despite a lack of official endorsement for universal cervical length assessment (except for the International Federation of Gynecology and Obstetrics, which has taken a leadership role), there are some green shoots appearing for those who espouse this policy.
Two adequately sized real-world studies have been published recently based on a universal cervical length screening program compared with historical controls. Son et al 80 from Chicago, IL, and Newnham et al 81 from Western Australia in well-conducted and planned studies both reported significant reductions in spontaneous PTB after the implementation of universal cervical screening despite a low overall incidence of PTB in their populations.
Son et al 80 introduced screening from 18 to 24 weeks in women without a history of PTB and with a recommendation for vaginal progesterone in women with a cervical length 20 mm. There was a significant reduction in the frequencies of spontaneous PTB following the introduction of screening at <37, <34, and <32 weeks despite a prevalence of cervical length 25 mm of 0.89% at screening and a rate of spontaneous PTB <34 weeks of 1.3%. The number needed to screen to prevent 1 case of preterm birth at <37 weeks of gestation was 143 and for <34 weeks was 500.
In the study of Newnham et al, 81 the implementation of a multifaceted program in 2014 that included universal cervical length screening and treatment with vaginal progesterone to women with a cervical length 25 mm was followed by a statistically significant 7.6% reduction in the rate of preterm birth in 2015. The effect extended from the 28e31 week gestational age group onward. In both of these studies, surveillance of the projects was admirable and motivation of both staff and patients was high.
A further cause for optimism in the 2015 survey 82 of all 78 accredited maternal-fetal medicine fellowship programs in the United States was that 68% reported implementation of a ajog.org Editorials universal cervical length screening program for low-risk women. I know of no equivalent initiatives in Europe, and it may not be long before PTB rates in the United States will be the envy of the world. There are important areas for future research, some of which have been discussed in the previous text. Perhaps the greatest priority is long-term follow-up studies along the lines of the OPPTIMUM trial, but calls for further research do not imply that we should not implement a program based on the IPD meta-analysis described in today's Journal.
Conclusion
What is described in the manuscript published in this issue of the Journal represents a perfect marriage of technology and pharmacy fulfilling all the criteria for an effective screening test. 15, 83 A simple ultrasound measurement of the cervix in the midtrimester (a biomarker) piggybacked onto an already existing screening test and a treatment for women at risk that is safe, efficacious, and cost effective, causing no discomfort or side effects that will make significant inroads into the greatest problem for mothers and babies worldwide. The IPD meta-analysis published today will hopefully be the final push toward universal cervical length measurement for all pregnant women in the midtrimester and vaginal progesterone for those with a short cervix.
Final thoughts
There was a time when changes in obstetric practice could be imposed on obstetricians without a shred of evidence to support them. In 1920 Joseph DeLee, the legendary American obstetrician at the Chicago Lying in Hospital and author of the best-selling obstetrical and gynecological textbook outlined his systematic approach to childbirth for physicians, which consisted of hospital delivery for all parturients, twilight sleep with scopolamine in the first stage of labor, ether anesthesia in the second, routine episiotomy and forceps delivery (ostensibly to prevent cerebral palsy), separation of mother and baby at birth, and avoidance of breast-feeding. This was widely adopted in the United States, and it took half a century to undo the harms that resulted from these interventionist policies.
Historically, there are many other instances when obstetricians have blindly followed poorly researched advice to the detriment of their patient's health. As a result we have turned full circle, and no new treatment can be introduced without putting it to several randomized trials with rigorous statistical analysis in which the chance association between treated and untreated or control has to be less than 1 in a hundred.
And then there have to be confirmatory studies, which they themselves have to be gathered together in meta-analyses to determine whether the overall shift to benefit is significant. And only then begins the long process of persuading the colleges and numerous specialist associations that they should recommend this new advance and organize appropriate training programs before finally it is put to the individual woman for her consent by her treating physician.
While this is laudable, it takes only one study that bucks the consensus to get cries for more and more studies. The point I want to make is whether we have perhaps gone too far and that overanalysis has led to indecision and impotence to do anything at all. Obviously all screening programs are resisted by governments because they are costly, but there is a big picture here, which is the terrible cost, both human and financial, of spontaneous preterm birth. Any simple strategy included in an already existing program that is safe, proven to be effective, and pays its way should be implemented.
The IPD meta-analysis published today will hopefully be the final push toward universal cervical length measurement for all pregnant women and vaginal progesterone for those with a short cervix.
-
